Olaris, Inc. to Attend Truist Securities AI Symposium

Olaris, Inc, a precision medicine company leveraging metabolomics and machine learning for the discovery and development of biomarkers of response (BoRs) to optimize treatments and patient outcomes, announced today Founder and CEO of Olaris, Dr. Elizabeth O’Day, will present virtually at Truist Securities’ AI Symposium – Biotech and Tools. The symposium will take place virtually on Tuesday, March 1, 2022.

Dr. O’Day’s presentation will discuss the unique combination of metabolomics and machine learning used by Olaris to develop diagnostics that let patients know they have the right diagnosis and are on the right path to treatment.

In addition to the speakers, the symposium also includes 3 panels, focusing on the application of AI to synthetic biology and therapeutics, the use of deep learning and quantum physics for drug development, and integrated platforms for AI-based drug discovery. The keynote will feature a discussion from Pfizer on the use of AI and the pharma industry in COVID vaccine development. The full agenda for the event is available at: https://www.openexc.com/wp-content/uploads/2022/02/AI-Symposium-Agenda-2.24.pdf.

Registration for the symposium is available free of charge via https://truist-securities-2022-ai-symposium-biotech-tools.videoshowcase.net/login. The presentation will also be available via a link posted at https://www.olarisbor.com/news on the day of the symposium.

About Olaris

Olaris strives to fundamentally change the way diseases are treated by leveraging our proprietary metabolomics and machine learning platform to identify biomarker response (BoR) signatures. Olaris develops BoR in vitro diagnostics (IVD) to enable patients, providers and biopharma to seek the most effective treatment. To learn more, visit http://www.olarisbor.com.

Share the article on social networks or by e-mail:

Comments are closed.